|
[1]
|
范雪, 徐明国. 川崎病发病机制及治疗研究进展[J]. 中国实用儿科杂志, 2021, 36(5): 339-344.
|
|
[2]
|
李天颂, 林炎浩, 刁仕明. 儿童不完全川崎病与完全川崎病临床特点对比分析[J]. 基层医学论坛, 2022, 26(8): 148-150.
|
|
[3]
|
Chang, L., Yang, H.W., Lin, T/Y and Yang, K.D. (2021) Perspective of Immunopathogenesis and Im-munotherapies for Kawasaki Disease. Frontiers in Pediatrics, 9, Article 697632. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
董彤. 病原体感染与川崎病发病机制关系的研究进展[J]. 国际儿科学杂志, 2020, 47(1): 18-21.
|
|
[5]
|
李瑞燕, 李晓辉, 吴泰相. 川崎病与病原微生物关系的Meta分析[J]. 临床儿科杂志, 2013, 31(1): 69-72.
|
|
[6]
|
董明星, 王喜霞, 焦富勇, 张维华. 川崎病基因多态性的研究进展[J]. 中国当代儿科杂志, 2023, 25(12): 1234- 1238.
|
|
[7]
|
樊志丹, 俞海国, 胡坚, 赖建铭. 中国儿童血管炎诊断与治疗系列专家共识之四——川崎病[J]. 中国实用儿科杂志, 2023(7): 481-488.
|
|
[8]
|
Sharma, C., Ganigara, M., Galeotti, C., et al. (2021) Multisystem Inflammatory Syndrome in Children and Kawasaki Disease: A Critical Comparison. Nature Reviews Rheumatology, 17, 731-748. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
焦富勇, 穆志龙, 杜忠东, 杨晓东, 沈捷, 向伟, 王虹. 儿童不完全性川崎病的诊治[J]. 中国当代儿科杂志, 2023, 25(3): 238-243.
|
|
[10]
|
Furusho, K., Kamiya, T., Nakano, H, et al. (1984) High-Dose Intravenous Gammaglobulin for Kawasaki Disease. Lancet, 2, 1055-1058. [Google Scholar] [CrossRef]
|
|
[11]
|
McCrindle, B.W., Rowley, A.H., Newburger, J.W., et al. (2017) Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Pro-fessionals from the American Heart Association. Circulation, 135, e927-e999. [Google Scholar] [CrossRef]
|
|
[12]
|
Guiducci, C., Gong, M., Xu, Z., et al. (2010) TLR Recogni-tion of Self Nucleic Acids Hampers Glucocorticoid Activity in Lupus. Nature, 465, 937-941. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Moszyński, K.W. (1970) Sprawie rozpoznawania i leczenia zatoru powietrznego [Diagnosis and Treatment of Air Embolism]. Neurologia i Neurochirurgia Polska, 4, 483-485.
|
|
[14]
|
Dominguez, S.R., Birkholz, M., Anderson, M.S., et al. (2019) Diagnostic and Treatment Trends in Chil-dren with Kawasaki Disease in the United States, 2006-2015. The Pediatric Infectious Disease Journal, 38, 1010-1014. [Google Scholar] [CrossRef]
|
|
[15]
|
Mahieu, P., Bonduelle, Y., Bernard, A., et al. (1984) Acute Diquat Intoxicatio. Interest of Its Repeated Determination in Urine and the Evaluation of Renal Proximal Tubule Integrity. Journal of Toxicology: Clinical Toxicology, 22, 363-369. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Wooditch, A.C. and Aronoff, S.C. (2005) Effect of Initial Cor-ticosteroid Therapy on Coronary Artery Aneurysm Formation in Kawasaki Disease: A Meta-Analysis of 862 Children. Pediatrics, 116, 989-995. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Chen, S., Dong, Y., Kiuchi, M.G., et al. (2016) Coronary Artery Complication in Kawasaki Disease and the Importance of Early Intervention: A Systematic Review and Meta-Analysis. JAMA Pediatrics, 170, 1156-1163. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Green, J., Wardle, A.J. and Tulloh, R.M. (2022) Cortico-steroids for the Treatment of Kawasaki Disease in Children. Cochrane Database of Systematic Reviews, 5, CD011188. [Google Scholar] [CrossRef]
|
|
[19]
|
Zhao, C.N., Du, Z.D. and Gao, L.L. (2016) Corticosteroid Therapy Might Be Associated with the Development of Coronary Aneurysm in Children with Kawasaki Disease. Chi-nese Medical Journal, 129, 922-928. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Yang, T.J., Lin, M.T., Lu, C.Y., et al. (2018) The Prevention of Coronary Arterial Abnormalities in Kawasaki Disease: A Meta-Analysis of the Corticosteroid Effectiveness. Journal of Microbiology, Immunology and Infection, 51, 321-331. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Franchin, G. and Diamond, B. (2006) Pulse Steroids: How Much Is Enough? Autoimmunity Reviews, 5, 111-113. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Guiducci, C., Gong, M., Xu, Z., et al. (2010) TLR Recognition of Self Nucleic Acids Hampers Glucocorticoid Activity in Lupus. Nature, 465, 937-941. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Newburger, J.W., Sleeper, L.A., McCrindle, B.W., et al. (2007) Ran-domized Trial of Pulsed Corticosteroid Therapy for Primary Treatment of Kawasaki Disease. The New England Journal of Medicine, 356, 663-675. [Google Scholar] [CrossRef]
|
|
[24]
|
Son, M.B. and Newburger, J.W. (2012) Management of Kawasaki Disease: Corticosteroids Revisited. Lancet, 379, 1571-1572. [Google Scholar] [CrossRef]
|
|
[25]
|
Singh, S., Sharma, A. and Jiao, F. (2016) Kawasaki Disease: Issues in Diagnosis and Treatment—A Developing Country Perspective. The Indian Journal of Pediatrics, 83, 140-145. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Okubo, Y., Michihata, N., Morisaki, N., et al. (2018) Association between Dose of Glucocorticoids and Coronary Artery Lesions in Kawasaki Disease. Arthritis Care & Research, 70, 1052-1057. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Son, M.B.F., Gauvreau, K., Tremoulet, A.H., et al. (2019) Risk Model Development and Validation for Prediction of Coronary Artery Aneurysms in Kawasaki Disease in a North American Population. Journal of the American Heart Association, 8, e011319. [Google Scholar] [CrossRef]
|
|
[28]
|
Mitani, M., Ehara, K., Araki, K., Anzo, M. and Bamba, M. (2017) Encephalopathy and Pancreatitis in a 3-Year-Old Girl with Kawasaki Disease. Pediatrics International, 59, 496-498. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Chang, L.S. and Kuo, H.C. (2020) The Role of Corticosteroids in the Treatment of Kawasaki Disease. Expert Review of Anti-Infective Therapy, 18, 155-164. [Google Scholar] [CrossRef] [PubMed]
|